Forte Biosciences Inc (FBRX)

$11.26 -0.05 (-0.49%)
Market Cap 140.68M
Revenue (ttm) 0.00
Net Income (ttm) -35.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 92,700
Avg Vol 110,500
Day's Range N/A - N/A
Shares Out 12.43M
Stochastic %K 36%
Beta 2.91
Analysts Strong Sell
Price Target $63.33

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 310 618 6994
Address:
3060 Pegasus Park Drive, Building 6, Dallas, United States
StressTestIQ
StressTestIQ Aug. 27 at 4:50 AM
$FBRX price stabilizing, could attract dip buyers.
0 · Reply
porky1963
porky1963 Aug. 25 at 2:08 PM
$FBRX feels like that i am the only one here.
0 · Reply
porky1963
porky1963 Aug. 20 at 7:55 AM
$FBRX strange moves again and insiders seem to hold a good chunk and keep adding like me.$CRE
0 · Reply
d_risk
d_risk Aug. 17 at 4:36 PM
$FBRX - Forte Biosciences, Inc. - 10Q - Updated Risk Factors FBRX flags heightened risks from clinical trial setbacks, heavy cash burn, sole reliance on FB102, expanded regulatory and compliance exposures, IP and third-party dependencies, market volatility, and new legal, fraud, and misconduct concerns—plus potential dilution and stock price pressure from future financings and insider sales. #Biotechnology #MarketVolatility #IntellectualProperty #RegulatoryCompliance #ClinicalTrialRisks 🟢 Added 🟠 Removed https://d-risk.ai/FBRX/10-Q/2025-08-14
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 12:30 PM
Chardan Capital has updated their rating for Forte Biosciences ( $FBRX ) to Buy with a price target of 61.
0 · Reply
porky1963
porky1963 Aug. 15 at 10:30 AM
$FBRX not all bad news then,seems to be looking up in 2026,will add a few premarket.will it make a splash today.
0 · Reply
porky1963
porky1963 Aug. 12 at 8:59 AM
$CRE $FBRX believe there is a meeting this week and we will get to know more .
0 · Reply
Raxothus
Raxothus Aug. 7 at 4:14 PM
EOD FOLLOW-UP – 08/07/25 Tracking continuation watch from 08/06 based on today’s highs vs prior close ❌ $CRE – Closed 6.30, hit 6.48 (+2.9%). Small gap and push over 6.26 watch level before fading. ✅ $FBRX – Closed 10.66, hit 11.64 (+9.2%). Gapped and cleared 10.77+ continuation level early. ❌ $EHTH – Closed 4.76, hit 4.74 (–0.4%). Failed to trigger clean open over 4.82, early weakness. ❌ $PLL – Closed 8.39, hit 9.06 (+8.0%), but failed to break 8.83 cleanly and reversed. ✅ $FLYE – Closed 6.63, hit 6.98 (+5.3%). Strong early push through 6.70 continuation level. 📊 Recap Total: 5 Winners: 2 Faders: 3 Accuracy: 40% ⚠️ $FBRX, and $FLYE cleared levels with momentum and clean structure. $EHTH, $CRE and $PLL lacked follow-through and failed to confirm clean setups. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups #FollowUp #Accountability
0 · Reply
Raxothus
Raxothus Aug. 6 at 7:37 PM
EOD CONTINUATION WATCHLIST - 08/06/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $CRE - 2.1x volume, 1.3% VWAP stretch, small float. Coiled above VWAP all day. Needs breakout over 6.26+ for continuation. $FBRX - 8.4x volume, 8.2% VWAP stretch, micro float. Strong close near HOD with momentum. Watching for gap and push over 10.77+. $EHTH - 5.8x volume, 8.8% VWAP stretch, small float. Held VWAP and surged late. Needs clean open over 4.82+ to extend. $PLL - 2.1x volume, 1.7% VWAP stretch, small float. Slow grind with Power Hour strength. Needs breakout over 8.83+ to confirm. $FLYE - 2.4x volume, 2.4% VWAP stretch, small float. Closed strong after VWAP hold. Needs push through 6.70+ with volume. Watching for gap and VWAP continuation only. Focus on volume + structure. No random holds. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 6:04 PM
$FBRX Brilliant piece that captures FBRX's situation perfectly. So if you want to update your understanding of FBRX or get to know FBRX better, this is essential reading. https://beyondspx.com/article/forte-biosciences-unpacking-the-fb102-opportunity-after-positive-celiac-data-fbrx
0 · Reply
Latest News on FBRX
Forte Biosciences, Inc. Announces Results and Provides Update

Aug 14, 2025, 4:01 PM EDT - 12 days ago

Forte Biosciences, Inc. Announces Results and Provides Update

Forte Biosciences Announces Pricing of $75 Million Public Offering

Jun 25, 2025, 12:28 AM EDT - 2 months ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Jun 24, 2025, 4:01 PM EDT - 2 months ago

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Jun 23, 2025, 7:18 AM EDT - 2 months ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Mar 31, 2025, 9:00 AM EDT - 5 months ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Feb 3, 2025, 9:00 AM EST - 7 months ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Forte Biosciences to Host R&D Day December 3, 2024

Nov 25, 2024, 9:00 AM EST - 9 months ago

Forte Biosciences to Host R&D Day December 3, 2024

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 20, 2024, 9:00 AM EST - 10 months ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Nov 14, 2024, 4:01 PM EST - 10 months ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

May 17, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Dec 1, 2023, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Nov 13, 2023, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 14, 2023, 10:50 AM EDT - 2 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Sep 6, 2023, 3:15 PM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

May 15, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Jan 12, 2023, 4:05 PM EST - 2 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Nov 14, 2022, 4:01 PM EST - 3 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 17, 2022, 8:00 AM EDT - 3 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Aug 15, 2022, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Jun 7, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

May 16, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Sep 6, 2021, 12:42 PM EDT - 4 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Why Forte Biosciences Stock Is Down Over 80% Today

Sep 3, 2021, 2:31 PM EDT - 4 years ago

Why Forte Biosciences Stock Is Down Over 80% Today

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 12:19 PM EDT - 4 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 3, 2021, 7:21 AM EDT - 4 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Forte Biosciences Just Plummeted 80%: Here's Why

Sep 2, 2021, 5:47 PM EDT - 4 years ago

Forte Biosciences Just Plummeted 80%: Here's Why

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Sep 2, 2021, 4:05 PM EDT - 4 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Aug 16, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

May 11, 2021, 7:24 AM EDT - 4 years ago

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 10, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

May 3, 2021, 4:30 PM EDT - 4 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Apr 9, 2021, 6:07 AM EDT - 4 years ago

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Apr 8, 2021, 6:59 PM EDT - 4 years ago

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Mar 29, 2021, 12:10 PM EDT - 4 years ago

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

AMGN AXP CAT IMOM JPM UNH VRA

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 24, 2021, 8:00 AM EDT - 4 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Mar 17, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Feb 23, 2021, 4:01 PM EST - 4 years ago

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st

Feb 18, 2021, 4:01 PM EST - 4 years ago

Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18, 2020, 5:36 PM EST - 5 years ago

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd

Nov 24, 2020, 4:05 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd

StressTestIQ
StressTestIQ Aug. 27 at 4:50 AM
$FBRX price stabilizing, could attract dip buyers.
0 · Reply
porky1963
porky1963 Aug. 25 at 2:08 PM
$FBRX feels like that i am the only one here.
0 · Reply
porky1963
porky1963 Aug. 20 at 7:55 AM
$FBRX strange moves again and insiders seem to hold a good chunk and keep adding like me.$CRE
0 · Reply
d_risk
d_risk Aug. 17 at 4:36 PM
$FBRX - Forte Biosciences, Inc. - 10Q - Updated Risk Factors FBRX flags heightened risks from clinical trial setbacks, heavy cash burn, sole reliance on FB102, expanded regulatory and compliance exposures, IP and third-party dependencies, market volatility, and new legal, fraud, and misconduct concerns—plus potential dilution and stock price pressure from future financings and insider sales. #Biotechnology #MarketVolatility #IntellectualProperty #RegulatoryCompliance #ClinicalTrialRisks 🟢 Added 🟠 Removed https://d-risk.ai/FBRX/10-Q/2025-08-14
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 12:30 PM
Chardan Capital has updated their rating for Forte Biosciences ( $FBRX ) to Buy with a price target of 61.
0 · Reply
porky1963
porky1963 Aug. 15 at 10:30 AM
$FBRX not all bad news then,seems to be looking up in 2026,will add a few premarket.will it make a splash today.
0 · Reply
porky1963
porky1963 Aug. 12 at 8:59 AM
$CRE $FBRX believe there is a meeting this week and we will get to know more .
0 · Reply
Raxothus
Raxothus Aug. 7 at 4:14 PM
EOD FOLLOW-UP – 08/07/25 Tracking continuation watch from 08/06 based on today’s highs vs prior close ❌ $CRE – Closed 6.30, hit 6.48 (+2.9%). Small gap and push over 6.26 watch level before fading. ✅ $FBRX – Closed 10.66, hit 11.64 (+9.2%). Gapped and cleared 10.77+ continuation level early. ❌ $EHTH – Closed 4.76, hit 4.74 (–0.4%). Failed to trigger clean open over 4.82, early weakness. ❌ $PLL – Closed 8.39, hit 9.06 (+8.0%), but failed to break 8.83 cleanly and reversed. ✅ $FLYE – Closed 6.63, hit 6.98 (+5.3%). Strong early push through 6.70 continuation level. 📊 Recap Total: 5 Winners: 2 Faders: 3 Accuracy: 40% ⚠️ $FBRX, and $FLYE cleared levels with momentum and clean structure. $EHTH, $CRE and $PLL lacked follow-through and failed to confirm clean setups. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups #FollowUp #Accountability
0 · Reply
Raxothus
Raxothus Aug. 6 at 7:37 PM
EOD CONTINUATION WATCHLIST - 08/06/25 Focused on stocks that held VWAP and pushed into Power Hour with strength $CRE - 2.1x volume, 1.3% VWAP stretch, small float. Coiled above VWAP all day. Needs breakout over 6.26+ for continuation. $FBRX - 8.4x volume, 8.2% VWAP stretch, micro float. Strong close near HOD with momentum. Watching for gap and push over 10.77+. $EHTH - 5.8x volume, 8.8% VWAP stretch, small float. Held VWAP and surged late. Needs clean open over 4.82+ to extend. $PLL - 2.1x volume, 1.7% VWAP stretch, small float. Slow grind with Power Hour strength. Needs breakout over 8.83+ to confirm. $FLYE - 2.4x volume, 2.4% VWAP stretch, small float. Closed strong after VWAP hold. Needs push through 6.70+ with volume. Watching for gap and VWAP continuation only. Focus on volume + structure. No random holds. #EOD #VWAP #Momentum #SmallCaps #DayTrading #ContinuationSetups
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 28 at 6:04 PM
$FBRX Brilliant piece that captures FBRX's situation perfectly. So if you want to update your understanding of FBRX or get to know FBRX better, this is essential reading. https://beyondspx.com/article/forte-biosciences-unpacking-the-fb102-opportunity-after-positive-celiac-data-fbrx
0 · Reply
porky1963
porky1963 Jul. 27 at 7:29 PM
$FBRX well done donald president of the usa,love or hate him he has played a good deal for all.he loves scotland and he his so happy there.lets all get into whiskey sales.watch biotech sales fly this week.
0 · Reply
porky1963
porky1963 Jul. 27 at 6:48 AM
$FBRX fly up into the sky please.
0 · Reply
porky1963
porky1963 Jul. 26 at 9:42 AM
$FBRX up then as predicted.
1 · Reply
porky1963
porky1963 Jul. 17 at 4:48 PM
$FBRX just again bought 683 units for 5k.
3 · Reply
porky1963
porky1963 Jul. 17 at 4:29 PM
$FBRX just bought 558 units for around 4k uk.
1 · Reply
Rnerdz
Rnerdz Jul. 14 at 6:18 PM
$FBRX why tho
0 · Reply
goalseeker
goalseeker Jul. 10 at 6:37 PM
$FBRX NOW WHAT?? come on ftards!
2 · Reply
Doozio
Doozio Jul. 9 at 11:33 PM
$FBRX chop chop huckleberries……
0 · Reply
TwongStocks
TwongStocks Jul. 8 at 12:11 PM
$FBRX New 13G filed this morning. Federated Hermes reporting they have beneficial ownership of 1,072,233 shares, 8.78%. https://www.sec.gov/Archives/edgar/data/1056288/000162363225000782/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
porky1963
porky1963 Jul. 5 at 11:01 AM
$FBRX keep your holding.big gains next few months.
0 · Reply
Pratik2024
Pratik2024 Jul. 1 at 11:58 PM
$ALLT $ASTS $CURV $FBRX $QXO Big Boys fight and kids sells in panic. Hahaha, Big Boys “Buy During Fear”. @CURV
0 · Reply
Pratik2024
Pratik2024 Jul. 1 at 4:23 PM
$ALLT $ASTS $CURV $FBRX $QXO "Buy During Fear" - strategy of purchasing assets when the market is experiencing a downturn or panic. Bought $CURV below 2.80 today. Let’s fly.
1 · Reply